Tryp Therapeutics has amassed an impressive leadership team with several decades of drug development experience, turning its attention to the next generation of psychedelic medicines.
Read More
As the promise of psychedelic medicines gains traction, the BBC has been examining the future of the industry.
Read More
The DEA will raise production quotas for psilocin and psilocybin from 50g, to 1,000g and 1,500g respectively.
Read MoreRed Light Holland exports 1.5kg of psilocybe truffles to Canada.
Filament Health to list on OTC market.
Field Trip opens psychedelic-assisted therapy clinic in Amsterdam.
PharmaTher releases 2021 financial results.
Little Green Pharma granted a licence to supply psilocybin in Australia.
Red Light Holland closes acquisition of Acadian Exotic Mushrooms.
Mydecine announces clinical trials for smoking cessation.
Nova Mentis expands research programme to target obesity and diabetes.
Three biotech stocks that Wall Street expects to double soon.
Health Canada approves Mydecine’s expansion of psilocybin cultivation.
Mindmed and BioXcel file patent to identify patient agitation.
Filament Health files patents to support research programmes.
Ketamine One to integrate Cognetivity Neurosciences’ technology into clinics.
SoundMind opens ketamine-assisted therapy clinic to treat PTSD.
Mycrodose Therapeutics expands its Californian laboratory.
Octarine Bio partners with Clerkenwell Health for clinical trials.
Algernon Pharmaceuticals releases data from preclinical trials.
Emyria releases results from MDMA-analogue studies.
Mindset Pharma trains rodents to differentiate between psilocybin and saline.
Neurocognitive effects of ketamine for depression examined.
Study points towards possible cognitive benefits of LSD microdosing.
Toronto moving forward with plan to decriminalise all drugs.
Michigan senators introduce bill to legalise entheogens.
Oregon aligns with Harvard Law School to implement psilocybin therapy.
Psilocybin advocates in Denver launch effort to allow communal use.